Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?

This is a matchup that the latecomer might not be able to win.It's obvious why Pfizer (PFE -0.11%) is eager to produce a medicine like Wegovy, Novo Nordisk's (NVO 2.93%) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan market at stake, there's likely more than enough room for multiple major competitors to find a home.But that doesn't mean the contenders have an equal chance of winning any competitive fight once such ...